Inrig, Jula K.
Travere Therapeutics,
United States
2025 Rank: 203828
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Urology & Nephrology
SubField 2:
General & Internal Medicine
Rank in SubField 1: 1296 out of 92052 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 203828 | 225873 |
| Total Cites | 428 | 501 |
| H-index | 9 | 9 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 12 | 12 |
| Number of Single+First Authored Papers | 26 | 26 |
| Total Cites to Single+First Authored Papers | 56 | 57 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 69 | 71 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 350 | 399 |
| Ratio of Total Citations to Distinct Citing Papers | 1.22 | 1.26 |
| Self-Citation Percentage |
14.57%
|
|
Inrig, Jula K.
Kitasato University School of Medicine,
Japan
2022 Rank: 175040
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Urology & Nephrology
SubField 2:
Nutrition & Dietetics
Rank in SubField 1: 1294 out of 79729 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 175040 | 196952 |
| Total Cites | 313 | 334 |
| H-index | 8 | 8 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 14 | 14 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 61 | 62 |
| Number of Single+First+Last Authored Papers | 31 | 31 |
| Total Cites to Single+First+Last Authored Papers | 72 | 73 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 275 | 294 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.14 |
| Self-Citation Percentage |
6.29%
|
|
Inrig, Jula K.
Kitasato University School of Medicine,
Japan
2021 Rank: 169915
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Urology & Nephrology
SubField 2:
Surgery
Rank in SubField 1: 1237 out of 76322 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 169915 | 193336 |
| Total Cites | 454 | 484 |
| H-index | 10 | 10 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 26 | 26 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 99 | 99 |
| Number of Single+First+Last Authored Papers | 31 | 31 |
| Total Cites to Single+First+Last Authored Papers | 111 | 111 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 400 | 427 |
| Ratio of Total Citations to Distinct Citing Papers | 1.14 | 1.13 |
| Self-Citation Percentage |
6.20%
|
|
Inrig, Jula K.
IQVIA Inc.,
United States
2020 Rank: 112294
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Urology & Nephrology
SubField 2:
Surgery
Rank in SubField 1: 871 out of 64516 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 112294 | 130330 |
| Total Cites | 415 | 457 |
| H-index | 11 | 11 |
| Hm-index | 3 | 3 |
| Number of Single Authored Papers | 5 | 5 |
| Total Cites to Single Authored Papers | 20 | 20 |
| Number of Single+First Authored Papers | 24 | 24 |
| Total Cites to Single+First Authored Papers | 100 | 101 |
| Number of Single+First+Last Authored Papers | 31 | 31 |
| Total Cites to Single+First+Last Authored Papers | 114 | 115 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 354 | 392 |
| Ratio of Total Citations to Distinct Citing Papers | 1.17 | 1.17 |
| Self-Citation Percentage |
9.19%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.